BBOT FY 2025 Earnings — BridgeBio Oncology Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

BBOTBridgeBio Oncology Therapeutics Inc.

$820M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$610,000

Operating Income

-$146M

Net Income

-$134M

EPS (Diluted)

$-4.30

Cash Flow

Operating Cash Flow

-$114M

Free Cash Flow

-$115M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$448M

Total Liabilities

$37M

Stockholders' Equity

$411M

Cash & Equivalents

$374M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$610,000	$0	—
Operating Income	-$146M	-$81M	-80.3%
Net Income	-$134M	-$74M	-80.5%